EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Responses to Medical Treatment in 192 Patients with Pancreatic Neuroendocrine Neoplasms Referred to the Copenhagen Neuroendocrine Tumour Centre in 2000–2020

Sofie Skovlund Petersen, Stine Møller, Cecilie Slott, Jesper Krogh, Carsten Palnæs Hansen iD, Andreas Kjaer iD, Pernille Holmager iD, Peter Oturai, Rajendra Singh Garbyal, Seppo W Langer, Ulrich Knigge, Mikkel Andreassen iD

Cancers · 18.03.2024 · 16 (6) · 1190

DOI: 10.3390/cancers16061190 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 18.03.2024. Verfasst von Sofie Skovlund Petersen und 11 weiteren Autor:innen. Beteiligte Einrichtung: ENETS Center of Excellence, Copenhagen University Hospital-Rigshospitalet, 2100 København, Denmark. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Danish Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Given the rarity and heterogeneity of pancreatic neuroendocrine neoplasms (pNEN), treatment algorithms and sequencing are primarily guided by expert opinions with limited evidence.

Aim

To investigate overall survival (OS), median progression-free survival (mPFS), and prognostic factors associated with the most common medical treatments for pNEN.

Methods

Retrospective single-center study encompassing patients diagnosed and monitored between 2000 and 2020 (n = 192).

Results

Median OS was 36 (95% CI: 26–46) months (99 months for grade (G) 1, 62 for G2, 14 for G3, and 10 for neuroendocrine carcinomas). Patients treated with somatostatin analogues (SSA) (n = 59, median Ki-67 9%) had an mPFS of 28 months. Treatment line (HR (first line as reference) 4.1, 95% CI: 1.9–9.1, p ≤ 0.001) emerged as an independent risk factor for time to progression. Patients with a Ki-67 index ≥10% (n = 28) had an mPFS of 27 months. Patients treated with streptozocin/5-fluorouracil (STZ/5FU) (n = 70, first-line treatment n = 68, median Ki-67 10%) had an mPFS of 20 months, with WHO grade serving as an independent risk factor (HR (G1 (n = 8) vs. G2 (n = 57)) 2.8, 95% CI: 1.1–7.2, p-value = 0.031). Median PFS was 21 months for peptide receptor radionuclide therapy (PRRT) (n = 41, first line n = 2, second line n = 29, median Ki-67 8%), 5 months for carboplatin and etoposide (n = 66, first-line treatment n = 60, median Ki-67 80%), and 3 months for temozolomide-based therapy (n = 56, first-line treatment n = 17, median Ki-67 30%).

Conclusion

(1) Overall survival was, as expected, highly dependent on grade; (2) median PFS for SSA was around 2.5 years without difference between tumors with Ki-67 above or below 10%; (3) STZ/5FU as first-line treatment exhibited a superior mPFS of 20 months compared to what has historically been reported for targeted treatments; (4) PRRT in G2 pNEN achieved an mPFS similar to first-line chemotherapy; and (5) limited treatment efficacy was observed in high-grade tumors when treated with carboplatin and etoposide or temozolomide.

Schlagwörter

Stichwörter der Autor:innen

chemotherapyeverolimuspancreatic neuroendocrine tumorspeptide receptor radionuclide therapysomatostatin analoguetreatment efficacy

Autor:innen und Institutionen

  • ENETS Center of Excellence, Copenhagen University Hospital-Rigshospitalet, 2100 København, Denmark.
  • Department of Endocrinology and Metabolism, Copenhagen University Hospital-Rigshospitalet, 2100 København, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, 1172 København, Denmark.
  • Department of Surgery and Transplantation, Copenhagen University Hospital-Rigshospitalet, 2100 København, Denmark.
  • Department of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital-Rigshospitalet, 2100 København, Denmark.
  • Department of Biomedical Sciences, University of Copenhagen, 1172 København, Denmark.

ORCID-Profile: Carsten Palnæs Hansen, Andreas Kjaer, Pernille Holmager, Mikkel Andreassen

Förderung

  • Danish Cancer Society

Zitieren

APA

Petersen, S. S., Møller, S., Slott, C., Krogh, J., Hansen, C. P., Kjaer, A., Holmager, P., Oturai, P., Garbyal, R. S., Langer, S. W., Knigge, U., & Andreassen, M. (2024). Responses to Medical Treatment in 192 Patients with Pancreatic Neuroendocrine Neoplasms Referred to the Copenhagen Neuroendocrine Tumour Centre in 2000–2020. Cancers, 16(6), 1190. https://doi.org/10.3390/cancers16061190

Vancouver

Petersen SS, Møller S, Slott C, Krogh J, Hansen CP, Kjaer A, et al. Responses to Medical Treatment in 192 Patients with Pancreatic Neuroendocrine Neoplasms Referred to the Copenhagen Neuroendocrine Tumour Centre in 2000–2020. Cancers. 2024;16(6):1190. doi:10.3390/cancers16061190

BibTeX
@article{Petersen2024,
  author = {Petersen, Sofie Skovlund and Møller, Stine and Slott, Cecilie and Krogh, Jesper and Hansen, Carsten Palnæs and Kjaer, Andreas and Holmager, Pernille and Oturai, Peter and Garbyal, Rajendra Singh and Langer, Seppo W and Knigge, Ulrich and Andreassen, Mikkel},
  title = {Responses to Medical Treatment in 192 Patients with Pancreatic Neuroendocrine Neoplasms Referred to the Copenhagen Neuroendocrine Tumour Centre in 2000–2020},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {6},
  pages = {1190},
  doi = {10.3390/cancers16061190}
}
Kostenlos starten →